Drugs Containing Excipient (Inactive Ingredient) AMINOBENZOIC ACID

« Back to Dashboard

Branded drugs containing AMINOBENZOIC ACID excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAXIMAGE DTPA	kit for the preparation of technetium tc 99m pentetate	65174-288	AMINOBENZOIC ACID

Generic drugs containing AMINOBENZOIC ACID excipient

Company	Ingredient	NDC	Excipient
Jubilant DraxImage Inc dba Jubilant Radiopharma	kit for the preparation of technetium tc 99m pentetate	65174-288	AMINOBENZOIC ACID
Curium US LLC	kit for the preparation of technetium tc 99m pentetate	69945-314	AMINOBENZOIC ACID
CellTrans Inc	donislecel	73539-001	AMINOBENZOIC ACID

Aminobenzoic Acid Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 27, 2026

4-Aminobenzoic acid, commonly called para-aminobenzoic acid or PABA, is a small-volume pharmaceutical and specialty-chemical material rather than a major standalone excipient. Its commercial value is driven more by use as a chemical intermediate, ultraviolet-absorbing ingredient, and specialty formulation component than by broad excipient demand. Public market reports do not provide a reliable, audited revenue series for pharmaceutical-grade aminobenzoic acid alone.

The core financial outlook is therefore volume-sensitive and application-dependent. Demand for PABA in pharmaceutical formulations is constrained by regulatory and tolerability issues, while demand for chemical intermediates and cosmetic applications provides greater commercial support.

What is aminobenzoic acid and which isomer is used in pharmaceuticals?

Aminobenzoic acid describes three positional isomers:

Isomer	Common name	Formula	Main commercial relevance
2-Aminobenzoic acid	Anthranilic acid	C7H7NO2	Pharmaceutical intermediates, dyes, fragrances
3-Aminobenzoic acid	Meta-aminobenzoic acid	C7H7NO2	Specialty intermediates and research chemicals
4-Aminobenzoic acid	Para-aminobenzoic acid, PABA	C7H7NO2	Sunscreen history, specialty formulations, pharmaceutical intermediates

This analysis focuses on 4-aminobenzoic acid, because PABA is the isomer most commonly associated with pharmaceutical and cosmetic use. Anthranilic acid has a separate industrial and pharmaceutical value chain and should not be combined with PABA in market estimates.

PABA is an aromatic aminocarboxylic acid. Its structure allows use in chemical synthesis, including the manufacture of benzocaine and other compounds related to local anesthetic chemistry. It has also been used in nutritional products and topical preparations.

How large is the pharmaceutical excipient market for aminobenzoic acid?

No authoritative public source reports a standalone global market size for pharmaceutical-grade PABA as an excipient. Commercial market reports typically combine PABA with broader categories such as specialty chemicals, pharmaceutical intermediates, nutraceutical ingredients, or cosmetic raw materials.

The addressable pharmaceutical excipient market is limited for four reasons:

1. PABA is not a high-volume multifunctional excipient such as microcrystalline cellulose, lactose, povidone, or magnesium stearate.
2. It has a narrow functional role in formulations.
3. Regulatory concern over sensitization limits topical use.
4. Much of its commercial demand comes from intermediate and non-pharmaceutical applications.

The relevant market should therefore be segmented as follows:

Segment	Demand profile	Commercial assessment
Direct pharmaceutical excipient	Low and formulation-specific	Niche
Pharmaceutical intermediate	More established	Larger than direct excipient demand
Sunscreen and topical active use	Historically important, now restricted in the United States	Declining or geographically limited
Nutraceutical and vitamin products	Consumer and regional demand	Variable
Cosmetic raw material	Limited by sensitization and product positioning	Selective
Research and specialty chemicals	Small-volume, higher-margin	Stable niche

A supplier that reports PABA revenue without separating these applications risks overstating the pharmaceutical excipient opportunity.

What are the main demand drivers for pharmaceutical-grade PABA?

The strongest demand driver is use as an intermediate rather than as an inactive ingredient. PABA is associated with the synthesis of benzocaine and related compounds, although the exact manufacturing route depends on the producer and product specification.

Pharmaceutical intermediates

Intermediate demand is linked to local anesthetics, chemical synthesis programs, and regional generic-drug production. This demand is more resilient than direct excipient demand because the material is consumed upstream and may not appear as an ingredient in the finished drug.

The main purchasing criteria are:

• Assay and impurity profile
• Residual solvents
• Heavy metals and elemental impurities
• Microbial limits where required
• Batch-to-batch consistency
• Documentation under GMP or suitable quality systems
• Supply continuity and change-control discipline

Topical and sunscreen applications

PABA was used historically as a sunscreen active ingredient. The FDA identified PABA as a sunscreen ingredient requiring additional safety and effectiveness support under the agency’s sunscreen regulatory framework. FDA’s 2019 proposed rule placed PABA among ingredients that lacked sufficient data for a generally recognized as safe and effective determination under the proposed framework (U.S. Food and Drug Administration, 2019).

PABA has also been associated with allergic contact dermatitis and sensitization concerns. These issues reduced its use in mainstream sunscreen products, particularly in the United States. Substitutes include octocrylene, avobenzone, octinoxate, zinc oxide, titanium dioxide, and newer regional filters.

Nutraceutical products

PABA is sometimes marketed in vitamin and dietary supplement products. This channel can generate demand but has weaker pharmaceutical-grade requirements and higher exposure to product claims, retailer policies, and consumer preferences. It should not be treated as equivalent to regulated drug-excipient demand.

What FDA regulatory status applies to aminobenzoic acid?

PABA does not have a regulatory status equivalent to a universally accepted inactive ingredient across oral, injectable, ophthalmic, and topical dosage forms.

FDA status

The relevant FDA questions are product-specific:

• Is PABA listed as an inactive ingredient for the intended route and dosage form?
• Is it used as an active ingredient rather than an excipient?
• Does the finished product comply with an applicable monograph or require an approved application?
• Does the supplier meet the quality and documentation requirements of the drug manufacturer?

The FDA Inactive Ingredient Database is the primary reference for determining whether a substance has precedent for a particular route and dosage form. A supplier cannot assume that acceptance in one topical or oral product establishes acceptability across other formulations (U.S. Food and Drug Administration, n.d.-a).

PABA’s former sunscreen role also requires separate treatment. A substance used as an active sunscreen ingredient is not automatically an excipient merely because it appears in a topical drug product.

European and international status

European regulatory treatment depends on the product category, route, and member-state or European Union framework. The European Medicines Agency’s excipient guidance emphasizes the need for safety information, quality specifications, and appropriate labeling where excipient effects are clinically relevant (European Medicines Agency, 2018).

Manufacturers selling PABA into Europe must separate:

• Pharmaceutical excipient supply
• Cosmetic ingredient supply
• Food or supplement supply
• Chemical-intermediate supply

Each channel has different documentation and compliance requirements.

What formulations are protected by aminobenzoic acid?

PABA itself is an old chemical entity and does not provide meaningful new-molecule patent protection. Any patent value is more likely to arise from a specific formulation, use, manufacturing method, salt, particle-size distribution, or combination product.

Potentially relevant claim categories include:

Claim type	Potential commercial relevance	Likely patent strength
PABA composition of matter	Core molecule	Very weak or expired
Specific salt or derivative	Formulation and processing	Case-specific
Topical delivery system	Stability, penetration, irritation control	Moderate if technically supported
Combination sunscreen	Product positioning and performance	Case-specific
Manufacturing process	Yield, purity, solvent reduction	Moderate if difficult to design around
Method of treatment	Route- and disease-specific	Depends on jurisdiction and claim scope
Particle size or polymorph	Dissolution and process performance	Potentially meaningful

How many patents cover aminobenzoic acid?

There is no meaningful single patent count for “aminobenzoic acid” without separating the isomers, jurisdictions, assignees, and claim types. The basic PABA molecule has been known for decades, so foundational composition patents are not a current barrier.

Relevant patent searches should distinguish:

• 4-aminobenzoic acid from anthranilic acid
• PABA from PABA derivatives
• Active sunscreen claims from excipient claims
• Manufacturing patents from formulation patents
• Expired patents from enforceable patent families
• U.S. patents from European, Chinese, Indian, and Japanese rights

A practical freedom-to-operate review should search the structure, CAS Registry Number 150-13-0, synonyms, salts, derivatives, and finished-product combinations. Patent risk is more likely to attach to a branded delivery system than to bulk PABA.

What is the Orange Book status of aminobenzoic acid?

PABA is not itself an Orange Book-listed drug product. The FDA Orange Book lists approved drug products and associated patents or exclusivity information, not raw materials as independent substances (U.S. Food and Drug Administration, n.d.-b).

Accordingly:

• There is no standalone PABA Orange Book exclusivity period.
• There is no PABA Paragraph IV pathway against the excipient itself.
• A Paragraph IV challenge would relate to an approved finished drug product containing PABA or a PABA-related formulation.
• Any listed patent would attach to the approved product, method of use, formulation, or delivery system.

When does aminobenzoic acid lose exclusivity?

PABA has no active-ingredient exclusivity timeline comparable to a recently approved pharmaceutical compound. The molecule is longstanding, and any core patent protection has expired.

The relevant exclusivity risks are product-specific:

Exclusivity type	Applicability to PABA
New chemical entity exclusivity	Not applicable to PABA itself
Orphan-drug exclusivity	Possible only for a qualifying finished product
Pediatric exclusivity	Product-specific
Formulation patent	Possible
Method-of-use patent	Possible
Manufacturing patent	Possible
Regulatory exclusivity for an approved drug	Applies to the finished product, not raw PABA

A generic manufacturer generally would not face an exclusivity barrier merely because it purchases pharmaceutical-grade PABA.

Which companies are challenging PABA products?

There is no identifiable, broad Paragraph IV litigation campaign directed at PABA as an excipient. Generic competition is more likely to occur at the finished-product level, especially for topical preparations, local anesthetics, and combination products.

Potential competitive participants include:

• Producers of PABA and related intermediates in China and India
• Pharmaceutical manufacturers producing benzocaine and related local anesthetics
• Contract manufacturers supplying regulated excipients
• Cosmetic and nutraceutical ingredient distributors
• Producers of alternative sunscreen filters

The absence of a major PABA-specific litigation docket indicates that commercial competition is primarily based on cost, qualification, documentation, and supply reliability rather than patent exclusion.

How strong is the patent estate for pharmaceutical-grade PABA?

The patent estate is weak for the molecule and potentially moderate for selected downstream applications.

Core molecule

The core compound is off-patent. A supplier cannot create durable exclusivity through routine purification, particle-size control, or pharmaceutical-grade packaging alone unless those attributes support enforceable technical claims.

Formulation technology

A formulation patent may have value if it improves:

• Skin tolerability
• Photostability
• Solubility
• Delivery to a target tissue
• Controlled release
• Compatibility with other active ingredients
• Stability under defined storage conditions

Claims that simply place PABA in a conventional cream, tablet, or capsule are vulnerable to validity and obviousness challenges.

Manufacturing technology

Process patents may create a more defensible position where they produce a measurable advantage, such as lower impurity levels, reduced solvent use, improved crystallization, or a cost-efficient route. Their value depends on whether competitors can use a different process while achieving the same specification.

What manufacturing and supply-chain barriers affect PABA?

PABA manufacturing is not generally viewed as a high-barrier pharmaceutical technology. The principal barriers are quality execution and customer qualification.

Key supply risks include:

• Dependence on a limited number of Asian producers
• Raw-material price volatility
• Batch contamination or inconsistent impurity profiles
• Changes in crystallization or drying conditions
• Regulatory inspection findings
• Customs and logistics disruption
• Failure to maintain validated analytical methods
• Supplier changes that trigger customer requalification

A pharmaceutical customer may require multiple successful batches, audit rights, change notifications, stability data, and a documented traceability system before approving a new supplier. These requirements raise switching costs even when the chemistry is readily available.

What is the financial trajectory for the aminobenzoic acid excipient market?

The financial trajectory is best described as stable-to-cautious for pharmaceutical applications and more variable across the broader PABA market.

Period	Expected market condition	Financial implication
Near term	Stable niche demand, limited direct excipient growth	Pricing remains competitive
Medium term	Intermediate demand tied to generic and specialty production	Revenue depends on volume and customer retention
Long term	Pressure from sunscreen substitution and alternative chemistries	Growth requires specialty positioning

Margin expansion is more likely through quality differentiation than through molecule ownership. Pharmaceutical-grade documentation, low-impurity material, validated manufacturing, and reliable supply can support a premium over technical-grade PABA.

Public-company revenue exposure is generally difficult to isolate because manufacturers report PABA within broader specialty-chemical, pharmaceutical-intermediate, or contract-manufacturing segments. No reliable public basis exists for attributing a specific percentage of a diversified supplier’s revenue to pharmaceutical-grade PABA.

How does PABA compare with competing pharmaceutical excipients?

PABA is materially less attractive than established multifunctional excipients for large-scale formulation platforms.

Attribute	PABA	Microcrystalline cellulose	Povidone	Benzocaine intermediate
Primary role	Specialty ingredient or intermediate	Binder and diluent	Binder and solubilizer	Active pharmaceutical intermediate
Volume potential	Low	High	High	Higher than direct PABA excipient use
Regulatory familiarity	Route-specific	Broad	Broad	Product-specific
Patent leverage	Low	Low to moderate by grade/process	Moderate by grade/process	Product and process-dependent
Substitution risk	High in many uses	Moderate	Moderate	Lower where synthesis is qualified
Pricing power	Limited	Limited to moderate	Moderate	Application-dependent

PABA’s best commercial position is in qualified, specialized supply rather than commodity-scale excipient production.

What generic launch risks exist for PABA-containing products?

Generic launch risk is moderate to high where PABA is used in a conventional formulation with no meaningful delivery advantage. Competitors can often source the material from multiple regions and design around nonessential formulation features.

Risk is lower when the product has:

• A validated impurity-controlled grade
• A difficult-to-reproduce particle profile
• A proprietary delivery system
• Strong stability data
• Regulatory precedent limited to a specific supplier or process
• A complex combination formulation

The primary barrier to entry is likely regulatory and technical qualification, not patent exclusivity.

Key Takeaways

• The commercially relevant isomer is 4-aminobenzoic acid, or PABA.
• PABA is a niche pharmaceutical excipient and a more significant specialty intermediate.
• No reliable public data supports a standalone global revenue figure for pharmaceutical-grade PABA.
• The core molecule is off-patent and has no meaningful standalone Orange Book exclusivity.
• Formulation and manufacturing patents can matter, but their strength is product-specific.
• FDA treatment must distinguish excipient use from PABA’s historical sunscreen-active use.
• Sensitization concerns and sunscreen substitution limit growth in U.S. topical applications.
• Revenue exposure is concentrated in specialty chemicals, intermediates, nutraceuticals, and regional topical products.
• Supply qualification, impurity control, GMP documentation, and continuity are the main commercial differentiators.
• Generic-entry risk is higher for conventional PABA formulations than for proprietary delivery systems.

FAQs

Is PABA the same as anthranilic acid?

No. PABA is 4-aminobenzoic acid, while anthranilic acid is 2-aminobenzoic acid. They are different positional isomers with different supply chains, uses, and regulatory profiles.

Is aminobenzoic acid an FDA-approved excipient?

PABA does not have blanket approval as an excipient for all dosage forms. Acceptability depends on the route, formulation, finished product, and FDA inactive-ingredient precedent.

Is PABA still used in sunscreen?

Use is limited, particularly in the United States, because of safety, sensitization, and regulatory concerns. Manufacturers have largely shifted toward alternative ultraviolet filters.

Can a supplier patent pharmaceutical-grade PABA?

A supplier is unlikely to obtain meaningful protection for the old molecule itself. Patentable opportunities may exist in a novel manufacturing process, formulation, delivery system, salt, or technically supported impurity-control method.

Is PABA more valuable as an excipient or as a pharmaceutical intermediate?

It is generally more commercially relevant as a pharmaceutical and specialty-chemical intermediate than as a broad-use excipient.

References

1. European Medicines Agency. (2018). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (2019). Tentative final monograph for over-the-counter sunscreen drug products. Federal Register, 84 Fed. Reg. 6204. https://www.federalregister.gov/

3. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. National Center for Biotechnology Information. (n.d.). PubChem compound summary: 4-Aminobenzoic acid. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/4-Aminobenzoic-acid